Biotech ETFs rose 90-400% over the past year while AI grabbed headlines. Why? Falling interest rates, positive trial results, and acquisition interest from Big Pharma. The lesson: Don’t chase one story. Markets reward investors who recognize overlooked sectors before Wall Street catches on.
About the Author
Michael Harvey has spent 30+ years teaching people how experienced investors actually think. He’s taught in conference rooms across New York City and founded Compounders Stock Market Academy, where he focuses on frameworks and long-term wealth building instead of stock tips. This article reflects patterns he’s observed repeatedly across market cycles—the importance of recognizing crushed sectors before Wall Street does.
The Story Everyone Missed
If you’ve watched financial news over the past six months, you’d think there’s only one industry worth investing in: Artificial Intelligence.
Every company either uses AI, is building AI, is thinking about AI, or knows somebody whose cousin once used AI.
Wall Street has been absolutely captivated.
But here’s what most investors missed.
While everyone was watching AI, biotechnology quietly became one of the market’s strongest sectors.
The Numbers Don’t Lie
Biotech Performance (Past 12 Months):
- SPDR S&P Biotech ETF (XBI): +90%
- Triple-leveraged biotech ETF (LABU): +400%
Not bad for an industry many investors had almost written off.
So why did biotech suddenly wake up? And what does this teach you about how to invest?
Why Biotechnology Is Having Its Moment
Several things happened simultaneously. Understanding why reveals something important about how markets work.
1. Investors Remembered What Biotechnology Actually Does
Biotechnology companies occasionally do something useful: they discover medicines that save lives.
Sounds obvious. But investors often forget the actual business while chasing headlines.
When you own a biotech stock, you’re not buying a story. You’re buying a company that might discover the next treatment for cancer, heart disease, or Alzheimer’s.
That’s real value.
2. Interest Rates Became Friendlier
This is crucial to understand.
Biotechnology companies spend years, sometimes decades, developing drugs before earning significant revenue. During that time, they burn cash funding research, clinical trials, and manufacturing.
When interest rates are high: Investors become impatient. They don’t want to fund a company that loses money for 10 years. Cost of capital is expensive.
When interest rates drop: Suddenly, investors are willing to fund tomorrow’s medical breakthroughs. The timeline doesn’t feel as painful.
This shift in the interest-rate environment made biotech attractive again.
3. Clinical Trial Results Started Coming In
Unlike many industries, biotechnology experiences what I call “scoreboard moments.”
- Phase 2 trial succeeds? Stock jumps 50%.
- Phase 3 trial fails? Stock crashes 40%.
- FDA approval? Company value transforms overnight.
Over the past year, positive trial results started flowing in. Investors saw proof that these companies weren’t just research experiments—they were making progress toward actual products.
4. Big Pharma Started Shopping
Here’s the acquisition story:
Many blockbuster drugs from the 1990s and 2000s are losing patent protection. When a drug’s patent expires, generic versions flood the market and revenue disappears.
Large pharmaceutical companies need replacements.
Building a new drug from scratch takes 10-15 years and billions of dollars. Buying an innovative biotech firm with a promising pipeline? Much faster.
Translation: Small biotech companies became attractive acquisition targets.
Wall Street noticed. Stock prices reflected it.
AI Showed Up Here Too
Here’s where the story gets interesting.
Artificial Intelligence is helping biotechnology too.
AI systems can:
- Examine millions of chemical compounds in seconds
- Analyze enormous genetic databases
- Identify promising drug targets
- Predict protein structures
- Help design better clinical trials
AI Doesn’t Replace Biology
But here’s what AI doesn’t do: it doesn’t invent miracle drugs.
Scientists still have to perform years of laboratory research, animal studies, and human clinical trials. Biology stubbornly insists on following the laws of biology.
Think of it this way:
Imagine asking someone to search every beach in Florida for a diamond.
Now imagine giving that person an extraordinarily accurate metal detector.
They still have to dig. But they’re digging in much better places.
That’s what AI is doing for biotechnology. It makes the research process faster and smarter. It doesn’t bypass the hard work.
The Investing Lesson: Don’t Chase One Story
One of the easiest mistakes investors make is assuming the market has only one winning story.
It almost never does.
While everyone was busy counting AI tokens and building AI data centers, biotechnology quietly reminded us that innovation comes in many forms.
One industry is teaching computers to think. The other is trying to help people live longer.
Both are building the future. Both deserve capital. Both will likely create wealth over the next decade.
How This Connects to What We Teach at Compounders
This is a perfect example of what we call the crushed sector strategy.
Here’s how it works:
- An entire sector falls out of favor (Biotech spent years underperforming as investors chased other ideas)
- Fundamentals improve (Interest rates drop, trial results come in, acquisition interest increases)
- Market starts to recognize the change (Stock prices begin rising)
- Early investors who saw the shift compound wealth (XBI up 90%, LABU up 400%)
This isn’t about predicting the future. It’s about recognizing powerful long-term trends—even when they’re unfolding just outside the spotlight.
The Bigger Pattern
As lifelong compounders, your job isn’t to chase headlines.
It’s to:
- Recognize when an entire sector has been written off too early
- Understand what changed (fundamentals, interest rates, sentiment, catalysts)
- Position yourself before the market catches on
- Hold discipline while everyone else is staring at the brightest light on stage
Sometimes, while everyone is focused on one story, another star is quietly getting ready for its encore.
Biotechnology just had one.
Key Takeaways
- Biotech outperformed AI over the past year despite receiving far less media attention
- Sectoral performance is driven by fundamentals, not headlines (interest rates, trial results, acquisition interest)
- Markets rarely have one winning story—innovation takes many forms
- The “crushed sector strategy” works by identifying when an entire industry has been written off, then watching fundamentals improve
- As an investor, your job is pattern recognition and discipline, not headline chasing
FAQ: Common Questions About Biotech and the Crushed Sector Strategy
Q: Why did biotech suddenly outperform?
A: Interest rates dropped, clinical trials succeeded, and Big Pharma started acquiring biotech firms. All simultaneously.
Q: Is AI replacing biotech?
A: No. AI accelerates biotech research but doesn’t replace the science. Both industries are growing.
Q: How do I identify crushed sectors?
A: Look for industries that have fallen out of favor, then watch for fundamental improvements (rates, trial results, acquisition interest, earnings recovery).
Q: Should I buy biotech stocks now?
A: We teach frameworks, not stock picks. Evaluate the business fundamentals and valuation using owner-investor thinking.
Ready to learn how to identify these patterns before the market catches on?
That’s what we teach at Compounders Stock Market Academy. Not stock picks. Not predictions.
How to think like the investors who actually compound wealth over decades.
Learn more about Compounders here.
Citations: SPDR S&P Biotech ETF (XBI) performance data via Yahoo Finance